Drug
Dexmecamylamine clinical trials
Also written TC-5214.
- studies test it
- 20
- open now
- 0
- in phase 3
- 5
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
- TC-5214
- 18
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2010 (8)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 8 |
| 2011 | 6 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 6
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 0
AstraZeneca (15) · Targacept Inc. (3) · Atacama Therapeutics (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dexmecamylamine is read from its arms, and is right about nine times in ten.
Testing it · 20
- Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar HyperhidrosisStatus unknownPhase 2Atacama TherapeuticsNCT04263623Written as Dexmecamylamine HCl
- Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar HyperhidrosisCompletedPhase 2Atacama TherapeuticsNCT03404570Written as Dexmecamylamine HCl
- Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive BladderCompletedPhase 2Targacept Inc.NCT01868516Written as dexmecamylamine
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedPhase 3AstraZenecaNCT01180400Written as TC-5214
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.CompletedPhase 3AstraZenecaNCT01197508Written as TC-5214
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)CompletedPhase 3AstraZenecaNCT01157078Written as TC-5214
- A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedPhase 3AstraZenecaNCT01152554Written as TC-5214
- A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderCompletedPhase 3AstraZenecaNCT01153347Written as TC-5214
- To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal FunctionCompletedPhase 1AstraZenecaNCT01240967Written as TC-5214
- TC-5214 as Augmentation Therapy in Patients With Refractory HypertensionTerminatedPhase 1/2Targacept Inc.NCT00899977Written as TC-5214
- TC-5214 as add-on the Treatment of Major Depressive DisorderCompletedPhase 2Targacept Inc.NCT00692445Written as TC-5214 + citalopram
- To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese SubjectsCompletedPhase 1AstraZenecaNCT01175564Written as TC-5214
- Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the HeartTerminatedPhase 1AstraZenecaNCT01359618Written as TC-5214
- A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.TerminatedPhase 2AstraZenecaNCT01288079Written as TC-5214
- To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic HypertensionTerminatedPhase 1AstraZenecaNCT01403922Written as TC-5214
- A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly SubjectsCompletedPhase 1AstraZenecaNCT01239771Written as TC-5214
- Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214WithdrawnPhase 1AstraZenecaNCT01500018Written as TC-5214
- Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214CompletedPhase 1AstraZenecaNCT01458899Written as TC-5214
- A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female VolunteersCompletedPhase 1AstraZenecaNCT01392820Written as TC-5214
- To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 DaysCompletedPhase 1AstraZenecaNCT01145768Written as TC-5214
Codes
What other systems call dexmecamylamine · ClinicalTrials.gg INT015147
- UNII (FDA) 5Y1141YI4UDEXMECAMYLAMINEConfirmed FDA, Wikidata
- NCI Thesaurus C166871DexmecamylamineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5Y1141YI4U | DEXMECAMYLAMINE | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166871 | Dexmecamylamine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.